Cost-effectiveness of reclassifying triptans in Australia: Application of an economic evaluation approach to regulatory decisions

Bonny Parkinson, Mutsa Gumbie, Henry Cutler, Natalie Gauld, Virginia Mumford, Philip Haywood

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Migraine is a common, chronic, disabling headache disorder. Triptans, used as an acute treatment for migraine, are available via prescription in Australia. An Australian Therapeutic Goods Administration (TGA) committee rejected reclassifying sumatriptan and zolmitriptan from prescription medicine to pharmacist-only between 2005 and 2009, largely on the basis of concerns about patient risk. Nevertheless, pharmacist-only triptans may reduce migraine duration and free up healthcare resources.

Objectives: To estimate the cost-effectiveness of reclassifying triptans from prescription-only to pharmacist-only in Australia.

Methods: The study design included decision-analytic modeling combining data from various sources. Behavior before and after reclassification was estimated using medical practitioner and patient surveys and also administrative data. Health outcomes included migraine frequency and duration as well as adverse events (AEs) discussed by the TGA committee. Efficacy and AEs were estimated using randomized controlled trials and observational studies.

Results: Reclassifying triptans will reduce migraine duration but increase AEs. This will result in 337 quality-adjusted life-years gained at an increased cost of A$5.9 million over 10 years for all Australian adults older than 15 years (19.6 million). The incremental cost-effectiveness ratio was estimated to be A$17 412/quality-adjusted life-year gained.

Conclusions: The incremental cost-effectiveness ratio is likely to be considered cost-effective by Australian decision makers. Serotonin syndrome, a key concern of the TGA committee, had little impact on the results. Further research is needed regarding pharmacist-only triptan use by migraineurs currently using over-the-counter medicines and by nonmigraineurs, the efficacy of triptans, and the risk of cardiovascular and cerebrovascular AEs and chronic headaches with triptans.
LanguageEnglish
Pages293-302
Number of pages10
JournalValue in Health
Volume22
Issue number3
Early online date24 Dec 2018
DOIs
Publication statusPublished - Mar 2019

Fingerprint

Tryptamines
Cost-Benefit Analysis
Migraine Disorders
Pharmacists
Headache Disorders
Prescriptions
zolmitriptan
Quality-Adjusted Life Years
Serotonin Syndrome
Sumatriptan
Costs and Cost Analysis
Decision Support Techniques
Information Storage and Retrieval
Therapeutics
Observational Studies
Randomized Controlled Trials
Delivery of Health Care
Health
Research

Keywords

  • behind-the-counter
  • cost effectiveness
  • economics
  • 5-HT receptor agonist
  • Legislation
  • nonprescription drugs
  • over-the-counter
  • prescription drugs
  • triptan

Cite this

@article{5c3629f0174445da91f0faa55251a8cc,
title = "Cost-effectiveness of reclassifying triptans in Australia: Application of an economic evaluation approach to regulatory decisions",
abstract = "Background: Migraine is a common, chronic, disabling headache disorder. Triptans, used as an acute treatment for migraine, are available via prescription in Australia. An Australian Therapeutic Goods Administration (TGA) committee rejected reclassifying sumatriptan and zolmitriptan from prescription medicine to pharmacist-only between 2005 and 2009, largely on the basis of concerns about patient risk. Nevertheless, pharmacist-only triptans may reduce migraine duration and free up healthcare resources.Objectives: To estimate the cost-effectiveness of reclassifying triptans from prescription-only to pharmacist-only in Australia.Methods: The study design included decision-analytic modeling combining data from various sources. Behavior before and after reclassification was estimated using medical practitioner and patient surveys and also administrative data. Health outcomes included migraine frequency and duration as well as adverse events (AEs) discussed by the TGA committee. Efficacy and AEs were estimated using randomized controlled trials and observational studies.Results: Reclassifying triptans will reduce migraine duration but increase AEs. This will result in 337 quality-adjusted life-years gained at an increased cost of A$5.9 million over 10 years for all Australian adults older than 15 years (19.6 million). The incremental cost-effectiveness ratio was estimated to be A$17 412/quality-adjusted life-year gained.Conclusions: The incremental cost-effectiveness ratio is likely to be considered cost-effective by Australian decision makers. Serotonin syndrome, a key concern of the TGA committee, had little impact on the results. Further research is needed regarding pharmacist-only triptan use by migraineurs currently using over-the-counter medicines and by nonmigraineurs, the efficacy of triptans, and the risk of cardiovascular and cerebrovascular AEs and chronic headaches with triptans.",
keywords = "behind-the-counter, cost effectiveness, economics, 5-HT receptor agonist, Legislation, nonprescription drugs, over-the-counter, prescription drugs, triptan",
author = "Bonny Parkinson and Mutsa Gumbie and Henry Cutler and Natalie Gauld and Virginia Mumford and Philip Haywood",
year = "2019",
month = "3",
doi = "10.1016/j.jval.2018.09.2840",
language = "English",
volume = "22",
pages = "293--302",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Blackwell Science",
number = "3",

}

Cost-effectiveness of reclassifying triptans in Australia : Application of an economic evaluation approach to regulatory decisions. / Parkinson, Bonny; Gumbie, Mutsa; Cutler, Henry; Gauld, Natalie ; Mumford, Virginia; Haywood, Philip.

In: Value in Health, Vol. 22, No. 3, 03.2019, p. 293-302.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cost-effectiveness of reclassifying triptans in Australia

T2 - Value in Health

AU - Parkinson, Bonny

AU - Gumbie, Mutsa

AU - Cutler, Henry

AU - Gauld, Natalie

AU - Mumford, Virginia

AU - Haywood, Philip

PY - 2019/3

Y1 - 2019/3

N2 - Background: Migraine is a common, chronic, disabling headache disorder. Triptans, used as an acute treatment for migraine, are available via prescription in Australia. An Australian Therapeutic Goods Administration (TGA) committee rejected reclassifying sumatriptan and zolmitriptan from prescription medicine to pharmacist-only between 2005 and 2009, largely on the basis of concerns about patient risk. Nevertheless, pharmacist-only triptans may reduce migraine duration and free up healthcare resources.Objectives: To estimate the cost-effectiveness of reclassifying triptans from prescription-only to pharmacist-only in Australia.Methods: The study design included decision-analytic modeling combining data from various sources. Behavior before and after reclassification was estimated using medical practitioner and patient surveys and also administrative data. Health outcomes included migraine frequency and duration as well as adverse events (AEs) discussed by the TGA committee. Efficacy and AEs were estimated using randomized controlled trials and observational studies.Results: Reclassifying triptans will reduce migraine duration but increase AEs. This will result in 337 quality-adjusted life-years gained at an increased cost of A$5.9 million over 10 years for all Australian adults older than 15 years (19.6 million). The incremental cost-effectiveness ratio was estimated to be A$17 412/quality-adjusted life-year gained.Conclusions: The incremental cost-effectiveness ratio is likely to be considered cost-effective by Australian decision makers. Serotonin syndrome, a key concern of the TGA committee, had little impact on the results. Further research is needed regarding pharmacist-only triptan use by migraineurs currently using over-the-counter medicines and by nonmigraineurs, the efficacy of triptans, and the risk of cardiovascular and cerebrovascular AEs and chronic headaches with triptans.

AB - Background: Migraine is a common, chronic, disabling headache disorder. Triptans, used as an acute treatment for migraine, are available via prescription in Australia. An Australian Therapeutic Goods Administration (TGA) committee rejected reclassifying sumatriptan and zolmitriptan from prescription medicine to pharmacist-only between 2005 and 2009, largely on the basis of concerns about patient risk. Nevertheless, pharmacist-only triptans may reduce migraine duration and free up healthcare resources.Objectives: To estimate the cost-effectiveness of reclassifying triptans from prescription-only to pharmacist-only in Australia.Methods: The study design included decision-analytic modeling combining data from various sources. Behavior before and after reclassification was estimated using medical practitioner and patient surveys and also administrative data. Health outcomes included migraine frequency and duration as well as adverse events (AEs) discussed by the TGA committee. Efficacy and AEs were estimated using randomized controlled trials and observational studies.Results: Reclassifying triptans will reduce migraine duration but increase AEs. This will result in 337 quality-adjusted life-years gained at an increased cost of A$5.9 million over 10 years for all Australian adults older than 15 years (19.6 million). The incremental cost-effectiveness ratio was estimated to be A$17 412/quality-adjusted life-year gained.Conclusions: The incremental cost-effectiveness ratio is likely to be considered cost-effective by Australian decision makers. Serotonin syndrome, a key concern of the TGA committee, had little impact on the results. Further research is needed regarding pharmacist-only triptan use by migraineurs currently using over-the-counter medicines and by nonmigraineurs, the efficacy of triptans, and the risk of cardiovascular and cerebrovascular AEs and chronic headaches with triptans.

KW - behind-the-counter

KW - cost effectiveness

KW - economics

KW - 5-HT receptor agonist

KW - Legislation

KW - nonprescription drugs

KW - over-the-counter

KW - prescription drugs

KW - triptan

UR - http://www.scopus.com/inward/record.url?scp=85058975819&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2018.09.2840

DO - 10.1016/j.jval.2018.09.2840

M3 - Article

VL - 22

SP - 293

EP - 302

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 3

ER -